Assessing HeartFlow (HTFL) Valuation After Mixed Price Performance And Rich Revenue Multiple

Event context and recent price action

HeartFlow (HTFL) has attracted fresh attention after a recent uptick in its share price, building on a 0.8% gain over the past day and a 10.5% move across the past week.

That short term strength sits alongside a 16.8% rise over the past month, set against a 19.1% decline across the past 3 months and a 6.5% negative return year to date. Together, these figures give investors a mixed recent picture.

See our latest analysis for HeartFlow.

Putting that into context, HeartFlow’s recent gains, including the 16.8% 1 month share price return, come after weaker 3 month and year to date share price returns. This suggests momentum has recently improved while the longer trend remains mixed.

If you are interested in how other healthcare AI names are trading, this is a good moment to scan the market using our screener for 34 healthcare AI stocks

With HeartFlow trading at US$27.08 versus an average analyst price target of US$37.67, the key question is whether this gap reflects undervaluation or whether the market is already pricing in future growth.

Most Popular Narrative: 29.8% Undervalued

HeartFlow’s most followed narrative points to a fair value of $38.60 per share versus the last close at $27.08, framing analysts’ earnings and growth expectations in a single target.

The transition of HeartFlow Plaque Analysis to a Category 1 CPT code in 2026, with defined Medicare payment rates in both clinic and hospital settings and commercial coverage already at 57% of U.S. lives, sets up a path for more routine clinical use that can add a new revenue stream and support gross margin mix over time.

Read the complete narrative.

Want to see what sits behind that valuation gap? The narrative leans heavily on faster revenue growth, improving margins and a future earnings multiple that assumes a very optimistic profit trajectory.

Result: Fair Value of $38.60 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this upbeat story can be knocked off course if coronary CT adoption slows, or if Plaque Analysis coverage and physician uptake take longer to build.

Find out about the key risks to this HeartFlow narrative.

Another view on valuation

Analyst narratives point to a fair value of $38.60, yet the current pricing tells a different story. On P/S, HeartFlow trades at 13.2x versus a 3.2x peer average, a 2.1x US Healthcare Services average and a fair ratio of 5.5x, which implies meaningful valuation risk if sentiment cools.

Before you lean too hard on any single target, it is worth stress testing what this rich revenue multiple assumes about future adoption, margins and competition, and asking whether you are comfortable paying so far above that fair ratio for growth that is still tied to unprofitable operations. See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment clearly split between rich valuation signals and growth potential, it makes sense to review the data yourself and move quickly to your own verdict. To see how the upside story stacks up against the downside, take a closer look at 3 key rewards and 2 important warning signs

Ready to hunt for more opportunities?

If HeartFlow has caught your attention, do not stop here. Use the Simply Wall St screener to find other ideas that could fit your portfolio before the crowd does.

• Target quality at a discount by scanning a curated set of 63 high quality undervalued stocks that combine strong fundamentals with prices that may not fully reflect their strengths.
• Look for more dependable cash flows by reviewing a hand picked group of 12 dividend fortresses that focus on higher yields with an emphasis on resilience.
• Protect your capital first by checking a selection of 72 resilient stocks with low risk scores built around companies with lower overall risk profiles and steadier track records.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com